Studies have shown that PTGS2 is upregulated in approximately 40% of BC patients (including ductal carcinoma in situ and invasive cancer) and associated with metastasis diseases, which reduced patients' survival rate [50]. This evidence concerns the gene PTGS2 and ductal breast carcinoma in situ.